HTLV-3/STLV-3 and HTLV-4 Viruses: Discovery, Epidemiology, Serology and Molecular Aspects by Mahieux, Renaud & Gessain, Antoine
Viruses 2011, 3, 1074-1090; doi:10.3390/v3071074 
 
viruses
ISSN 1999-4915 
www.mdpi.com/journal/viruses 
Review 
HTLV-3/STLV-3 and HTLV-4 Viruses: Discovery, 
Epidemiology, Serology and Molecular Aspects  
Renaud Mahieux 
1,2,3 and Antoine Gessain 
4,5,*  
1  Equipe Oncogenèse Rétrovirale, INSERM-U758 Virologie Humaine, 69364 Lyon cedex 07, 
France; E-Mail: renaud.mahieux@ens-lyon.fr 
2  Ecole Normale Supérieure de Lyon, 69364 Lyon cedex 07, France 
3  IFR 128 Biosciences Lyon-Gerland, 69364 Lyon cedex 07, France 
4  Unité d'Epidémiologie et Physiopathologie des Virus Oncogènes, Département de Virologie, 
Institut Pasteur, 28 rue du Dr Roux, 75015 Paris, France 
5  CNRS URA 3015, Institut Pasteur, 28 rue du Dr Roux, 75015 Paris, France 
*  Author to whom correspondence should be addressed; E-Mail: agessain@pasteur.fr;  
Tel.: +33-1-45-68-89-06; Fax: +33-1-40-61-34-65. 
Received: 11 May 2011; in revised form: 21 June 2011 / Accepted: 6 July 2011 /  
Published: 8 July 2011 
 
Abstract: Human T cell leukemia/lymphoma virus Type 1 and 2 (HTLV-1 and HTLV-2), 
together  with  their  simian  counterparts  (STLV-1,  STLV-2),  belong  to  the  Primate  T 
lymphotropic viruses group (PTLV). The high percentage of homologies between HTLV-1 
and  STLV-1  strains,  led  to  the  demonstration  that  most  HTLV-1  subtypes  arose  from 
interspecies transmission between monkeys and humans. STLV-3 viruses belong to the 
third PTLV type and are equally divergent from both HTLV-1 and HTLV-2. They are 
endemic in several monkey species that live in West, Central and East Africa. In 2005, we, 
and others reported the discovery of the human homolog (HTLV-3) of STLV-3 in two 
asymptomatic inhabitants from South Cameroon whose sera exhibited HTLV indeterminate 
serologies.  More  recently,  two  other  cases  of  HTLV-3  infection  in  persons  living  in 
Cameroon were reported suggesting that this virus is not extremely rare in the human 
population  living  in  Central  Africa.  Together  with  STLV-3,  these  human  viral  strains 
belong to the PTLV-3 group. A fourth HTLV type (HTLV-4) was also discovered in the 
same geographical area. The overall PTLV-3 and PTLV-4 genomic organization is similar 
to that of HTLV-1 and HTLV-2 with the exception of their long terminal repeats (LTRs) 
that contain only two 21 bp repeats. As in HTLV-1, HTLV-3 Tax contains a PDZ binding 
motif  while  HTLV-4  does  not.  An  antisense  transcript  was  also  described  in  HTLV-3 
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transfected cells. PTLV-3 molecular clones are now available and will allow scientists to 
study the viral cycle, the tropism and the possible pathogenicity in vivo. Current studies are 
also aimed at determining the prevalence, distribution, and modes of transmission of these 
viruses, as well as their possible association with human diseases. Here we will review the 
characteristics of these new simian and human retroviruses, whose discovery has opened 
new avenues of research in the retrovirology field. 
Keywords:  HTLV-3;  STLV-3;  HTLV-4;  Tax;  emerging  virus;  retrovirus;  interspecies 
transmission; transformation 
 
1. Introduction 
The  HTLV-1,  HTLV-2  and  HTLV-3  human  T  lymphotropic  viruses  as  well  as  their  STLV-1, 
STLV-2 and STLV-3 related simian counterparts constitute the primate T-cell lymphotropic viruses 
(PTLV) group [1]. These different delta retroviruses share a number of epidemiological and molecular 
characteristics. While PTLV-1 and PTLV-2 strains have been extensively studied since the 1980s, 
studies on PTLV-3 are more recent and have increased in number since the discovery of HTLV-3 in 
2005 [2,3]. HTLV-4, the fourth human HTLV retrovirus, was also discovered in 2005, but a simian 
counterpart of this virus has not been identified to date [3,4]. We will review here the characteristics of 
these new simian and human retroviruses, whose discovery has opened new avenues of research in the 
retrovirology field. 
2. STLV-3 Discovery and Epidemiological Characteristics 
The  first  strain  of  STLV-3  (strain  STLV-L/PH-969)  was  isolated  in  1994,  after  the  long-term  
co-culture of human cord blood lymphocytes with the peripheral blood mononuclear cells (PBMCs), 
obtained from an  Eritrean  sacred baboon  (Papio hamadryas)  that  had been  kept  in captivity in  a 
research  laboratory  in  Leuven  (Belgium)  [5].  The  sera  of  two  baboons  tested  weakly  positive  by 
immunofluorescence  using  HTLV-1  infected  MT2  cells  as  a  source  of  viral  antigens  and  with  a 
commercial  HTLV1/2  ELISA  assay.  They  also  exhibited  reactivities  against  the  p24
gag  and  the 
rgp21
env proteins when tested with a commercial HTLV Western Blot (WB) assay. In addition, one of 
them reacted with the HTLV-2 gp46 specific K55 envelope peptide, resulting in a WB pattern that was 
indistinguishable from that of the HTLV-2 positive control [5]. The proviral sequence displayed a 
significant nucleotide divergence from that of the HTLV-1 and HTLV-2 prototypical sequences (40% 
and 38%, respectively). It was thus considered as the third lineage of the PTLV group and labeled as 
STLV-3. Beginning in December 2001, a series of other STLV-3 strains were then reported by several 
investigators, in a number of different West, Central and East African monkey species (Cercocebus 
Torquatus,  Cercopithecus  nictitans,  Papio  papio,  Theropithecus  gelada,  Cercopithecus  cephus, 
Lophocebus albigena, Cercocebus agiles and lastly Cercopithecus mona) (Figure 1). Some of these 
STLV-3  viruses  were  present  in  wild-caught  and/or  wild-born  animals  living  in  Cameroon  [6–8], 
Nigeria [9] or Ethiopia [10]. In other cases, the animals had been kept in captivity either in France in Viruses 2011, 3                                       
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an ethological center [11], or in US zoos [12]. Of importance, and as with the STLV-L/PH969 STLV-3 
isolate, most STLV-3 serologies resembled an HTLV-2 pattern (gag
p24 > gag
p19 and env
gp21 GD21, +/− 
env
gp46 K55) as determined with an HTLV-1/2 commercial Western-blot assay (HTLV2-4 WB) and/or 
with INNOLIA kits [7–10,12]. However, in few cases, the Western-blot patterns were considered as 
HTLV indeterminate or "HTLV-1 like” based on the manufacturer’s criteria [12].  
Figure  1.  Current  known  geographical  distribution  of  STLV-3,  HTLV-3  and  HTLV-4 
viruses in the African continent. HTLV-3 and HTLV-4 are designated in bold. 
 
 
In comparison to STLV-1, very limited data is available on the major epidemiological determinants 
(i.e.,  age,  sex,  modes  of  transmissions)  of  STLV-3  infection  within  infected  non-human  primates 
(NHP).  Indeed,  to  date,  most  studies  were  performed  in  wild-caught  monkeys  [8,10,13,14].  The 
prevalence of STLV-3 infection in such studies varies greatly according to the studied NHP species, 
the geographical location of the animals and the methodologies used for animals sampling (living 
monkeys kept as pets in villages, dead animals with bush-meat samples, collection of blood or of dried 
blood spots). Regarding STLV-3 infection among captive monkeys, the initial paper reported that two Viruses 2011, 3                                       
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out of 13 Papio hamadryas, originating from Eritrea and kept in Leuven, were infected [5]. In the 
study performed on Papio papio kept in a laboratory in France, but originating from Senegal, 4 out of 
the 9 baboons were found to be infected with STLV-3 [11]. Lastly, the work on the captive Gelada in 
US zoos indicated that 5 out of 23 animals were STLV-3 infected. In the latter group, mother-to-
offspring transmission as well as horizontal transmission were suggested [12]. As is the case for the 
PTLV-1, a high genetic stability was also demonstrated by studying both parental and descendant 
strains over time [12]. STLV-3 infection has not been linked to any pathology so far. An interesting 
observation was made when researchers noticed that STLV-1 and STLV-3 can be found in the same 
primate  species,  as  exemplified  by  the  presence  of  these  two  viruses  in  Cercopithecus  nictitans, 
Cercocebus agilis, and Lophocebus albigena [4,14]. A nice work performed in south Cameroon also 
reported cases of STLV-1/STLV-3 co-infections in the same animal [8]. 
Sequence comparisons of STLV-3 full-length proviruses pointed out that these strains are highly 
divergent  from  HTLV-1,  HTLV-2,  or  STLV-2  prototype  sequences  (around  40%  nucleotide 
divergence). Based on partial or complete sequence analysis, the STLV-3 lineage is now currently 
considered  to  be  composed  of  four  main  subtypes  (A,  B,  C,  D)  that  roughly  correspond  to  the 
geographical source of the strains. The subtype A comprises strains from East Africa (Ethiopia and 
Eritrea), the subtype B corresponds to strains from West and Central Africa, while the subtypes C and 
D comprise strains from Central Africa (Figure 2). 
3. HTLV-3 Discovery, Serological and Epidemiological Characteristics  
In 2005, we and others (W. Switzer and W. Heneine's team from the Center for Diseases Control) 
reported the discovery of HTLV-3, a third HTLV type, in two Cameroonese asymptomatic individuals 
living in the rainforest area of the southern part of the country [2,3] (Table 1 and Figure 3). Their sera 
led to an HTLV positive serology when tested with commercial HTLV-1/2 ELISA kits, but to an 
HTLV  indeterminate  serology  when  tested  with  HTLV-1/2  commercial  Western-blot  assays  
(Figure 4). In one case (Pyl43), the WB profile displayed a clear reactivity against gag
p19 and against 
the HTLV-1 env
gp46 MTA-1 peptide [2], while in the other (2026ND), the WB showed reactivity 
against  gag
p19,  gag
p24,  and  env
GD21  as  well  as  a  weak  signal  against  the  HTLV-1  env
gp46  MTA-1 
peptide [3]. These two viruses were not isolated in culture but their proviruses were detected using a 
series of PCR primers designed to amplify all known HTLVs and STLVs. More recently, the same 
teams reported the discovery of two additional HTLV-3 strains. The first (Lobak18) was discovered by 
our laboratory in another Cameroonese individual [15]. His serum also gave rise to a different WB 
profile, being considered as HTLV indeterminate (clear gag
p19, gag
p24, env
GD21 reactivity and weak 
HTLV-2 gp46 env
K55 signal). The sequence of the virus is closely related to the first HTLV-3 strain 
(Pyl43) [16]. Both viruses belong to the PTLV-3 subtype B. The fourth HTLV-3 strain (Cam 2013AB) 
was reported by the CDC team [17]. It originated from a hunter, living in Southern Cameroon, who 
exhibited a HTLV indeterminate WB seroreactivity. Its sequence is  closely related to  a  divergent 
STLV-3  virus  (Cmo  8699AB)  previously  found  in  a  wild  Cercopithecus  mona  from  a  close 
geographical area [4]. These two HTLV-3/STLV-3 belong to the PTLV-3 subtype D (Figure 2). The 
main characteristics of the four HTLV-3 strains are reported in Table 1. Viruses 2011, 3                                       
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Figure 2. Phylogenetic tree showing the relationship between PTLV-1, PTLV-2, PTLV3, 
and HTLV-4. Unrooted tree generated with the neighbor-joining method, performed with 
the PAUP program using the 7075 bp of the concatanated gag-pol-env-tax genes with all 
the complete sequences of PTLVs available in GenBank. Branch lengths are drawn to 
scale. The human HTLV-3 and HTLV-4 strains are indicated in bold. Recent data based on 
shorter fragments of more STLV-3 strains confirmed that PTLV-3s are separated according 
to their geographical origin with four main distinct lineages (A, B, C, D). Mac B43 strain is a 
highly divergent STLV-1 originating from Macaca arctoides. It is considered as an STLV-5 
by some authors due to its great genetic diversity compared to STLV-1/HTLV-1 strains. 
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Table 1. Main epidemiological and HTLV serological characteristics of the 5 individuals infected either by HTLV-3 (n = 4) or HTLV-4  
(n = 1). The five infected individuals lived in the forest area of South Cameroon and were hunters of non-human primates. 
Identification  Age 
(year)  Sex  Ethnic Group  Screening Test  W.Blot HTLV 2.4  Inno-Lia  Reference 
HTLV-3 Pyl 43  62  Male  Bakola Pygmy  Weak IFA + MT2  P19, and weak MTA-1 
Weak Gag p19 I/II 
Env gp46 I/II, Weak Gag p19 I 
Weak Env gp46 I 
Env gp46 II  
[2] 
HTLV-3 2026 ND  63  Male  NP  ELISA +  P19, P24, GD21, and 
weak MTA-1 
Weak P24 I/II  
Env gp21  [3] 
HTLV-3 Lobak 18  56  Male  Baka Pygmy  IFA + MT2  P19, P24, GD21, K55 
Weak Gag P19 I/II  
Weak Env gp46 I/II  
Env gp21 I/II 
[15] 
HTLV-3 
Cam2013AB  32  Male  Bantu  ELISA +  P24, P28, GD21    [17] 
HTLV-4 1863 LE  48  Male  NP  ELISA +  P19, weak P24, P26, P28, 
weak GD21, weak K55. 
Gag p19 I/II  
Gag p24 I/II  
Env gp46 I/II  
Env 21 I/II  
Env gp46 I  
[3] Viruses 2011, 3                                       
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Figure 3. Geographical distribution of the four HTLV-3 and the unique HTLV-4 viruses 
reported  in  Cameroon.  These  viruses  originated  from  individuals  (either  Pygmies  or 
Bantus) living in villages or settlements of the rainforest of South Cameroon. This area is a 
region  of  high  diversity  for  NHPs,  many  of  them  being  infected  by  different  STLV-1 
and/or  3  viruses.  The  different  human  isolates  are  indicated  with  either  a  green  circle 
(HTLV-3) or in blue (HTLV-4). The two shaded areas correspond to two nature reserves, 
the habitat of a large variety of non-human primates. 
 
 
An important question concerns the origin of HTLV-3 in humans. Based on the close homologies 
between  some  STLV-3  and  HTLV-3  strains,  and  consistent  with  what  is  known  for  the  PTLV-1 
viruses, it is very tempting to suggest a zoonotic origin of HTLV-3 after interspecies transmission from 
STLV-3  infected  NHP  to  humans.  The  diversity  of  HTLV-3  implies  several  episodes  of  such 
transmission.  Exactly  when  these  episodes  occurred  is  currently  unknown.  However,  the  limited 
divergence that is observed between some STLV-3 and HTLV-3 strains (such as Pyl43, Lobak 18 and 
CTO 604) strongly suggests a recent non-human primate to human transmission [17]. Lastly, even if it 
is quite clear that the transmission per se occurred between hunter and NHP contact, the exact mode(s) 
of transmission  remains  speculative. Theoretically, any contact between an  STLV-3-infected body 
fluid from a NHP and blood or muco-cutaneous tissue (with or without a lesion) could allow such 
zoonotic  transmission.  However,  it  is  worthwhile  to  note  that  none  of  the  four  infected  HTLV-3 
persons ever reported a bite wound by an NHP [2,3,15,17]. This could be coincidental, or this may Viruses 2011, 3                                       
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suggest that STLV-3 is not transmitted like the simian foamy virus (SFV), for which severe bites, 
whereby infected saliva and blood of the hunter most probably mix, appears as a major risk factor for 
transmission [18–20]. In the SFV situation, the presence of SFV in the saliva of NHPs has been well 
demonstrated. For STLV-3 infection, the cutting-up and butchering of NHP game may be more likely 
to be the route of STLV-3 transmission than bites. 
Figure  4.  Serological  pattern  of  HTLV-1,  HTLV-2,  STLV-3  and  HTLV-3Pyl43  strain.  
(A) Western blot from MP Biomedicals (HTLV Blot 2.4 version); (B) Line immunoassay 
from Immunogenetics (INNO-LIA HTLVI/II Score). Lane 1: HTLV-1 positive control. 
Lane  2:  HTLV-2  positive  control.  Lanes  3  and  4:  STLV-3  positive  controls.  Lane  5: 
negative  control.  Lane  6:  HTLV-3/Pyl43  sample.  Lanes  7  and  8:  Two  samples  of  
HTLV-3/Lobak18  sampled  a  few  months  apart.  Infection  with  the  other  two  HTLV-3 
strains (2026ND and CAM2031AB) led to different Western-blot patterns when compared 
to HTLV-3pyl43 [3,17]. (Adapted from [15]).  
 Viruses 2011, 3                                       
 
 
1082 
4. HTLV-4, Another Retrovirus Found in Humans 
The fourth HTLV type (HTLV-4) consists only, so far, of a unique human strain, whose provirus 
was also found in the PBMCs obtained from a hunter living in Cameroon [3]. The serum from the 
infected individual also reacted with both HTLV-1/2 ELISA and HTLV-1/2 WB commercial kits. The 
WB profile was that of an HTLV indeterminate serum, with the presence of a strong reactivity against 
the  HTLV-1  gag
p19,  weak  reactivities  against  env
rgp21  and  HTLV-2  K55  env
gp46  peptide  and  no 
reactivity against gag
p24 (Table 1). The complete sequence of HTLV-4 is now available. The provirus 
is 8791 bp long and its sequence is equidistant from HTLV-1, HTLV-2 and HTLV-3, sharing only  
62–71%  nucleotide  identity  with  each  of  them  [21].  Detailed  phylogenetic  analysis  shows  that  
HTLV-4 is clearly a monophyletic viral group and is considered as the oldest known PTLV-lineage. 
Given the previous data on PTLV-1 and PTLV-3, it is also expected that a monkey species is infected 
or has been infected in the past with the simian equivalent of HTLV-4. However, until now and despite 
the screening of a large number of monkeys from Cameroon, the search for such a virus has been 
unsuccessful [4,14]. 
5. HTLV-3/STLV-3 Genomic Characterization 
The overall PTLV-3 genomic organization is similar to that of HTLV-1 and HTLV-2, with the 
presence of gag, pro, pol, env, tax and rex genes (Figure 5). However, LTR sequence analyses also 
revealed that the 5’ PTLV-3 promoter contains only two 21-bp repeats (also named Tax Responsive 
Element, TRE), while the HTLV-1 or HTLV-2 LTRs possess three of these sequences. The analysis of 
the full length HTLV-3 sequences [15–17,22] demonstrated that the HTLV-3 genome organization is 
similar to that of HTLV-1 and HTLV-2 and to that of central African STLV-3 strains.  
HTLV-3  and  STLV-3  viruses  share  the  same  genomic  organization  and  are  highly  related  in 
sequence  (87  to  99%  identity)  [16,22,23].  Surprisingly,  one  of  the  published  HTLV-3  sequences 
(Pyl43) contains a 366 bp deletion in its proximal pX region [16]. Importantly, this deletion should not 
affect Env or Tax/Rex expression. The remaining HTLV-3 published proviruses do not present this 
deletion. As in HTLV-1 carriers, the Tax protein is expressed in vivo, both in a subset of STLV-3 
infected animals and in the only HTLV-3 carrier tested [23]. 
5.1. PTLV-3: Characterization of the Tax Protein  
Some HTLV-3 Tax transactivator protein functions have been characterized. Even if it was shown 
that HTLV-1 and HTLV-3 Tax protein do not similarly bind p300, it was demonstrated that Tax1 and 
Tax3 proteins display a number of key similarities including the presence of a PDZ binding motif, 
which is absent from the Tax2 protein [22,23]. This sequence was previously shown to be critical for 
the  ability  of  the  Tax1  protein  to  transform  cells  in  vitro.  The  results  also  revealed  that  Tax3  is 
functionally closely related to the transforming HTLV-1 Tax. It is indeed able to transactivate cellular 
promoters, to activate the NF-B pathway, to bind the CBP transcription co-activator and can also 
repress  the  function  of  the  p53  tumor  suppressor  factor.  Altogether,  these  results  suggested  that  
HTLV-3 might be pathogenic in vivo. As stated above, cases of STLV-1/STLV-3 naturally co-infected 
animals  have  been  described. It was  therefore interesting to show that Tax3 can  transactivate the Viruses 2011, 3                                       
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heterologous HTLV-1 promoter [16,23]. Whether this could or not accelerate the occurrence of a 
possible disease in the co-infected animals remains to be determined. 
Figure 5. HTLV-3 genomic organization. HTLV-3 ORFs and transcription map. A scheme 
of the HTLV-3 genome, alternatively spliced mRNAs, and putative proteins encoded by 
each mRNA is shown. ORFs are indicated by boxes. gag, pro, pol, env, tax/rex and APH-3 
transcripts were amplified from 293T cells transfected with an HTLV-3 molecular clone or 
from  STLV-3  infected  cells  [24,25].  Gray:  LTR;  blue:  structural  and  enzymatic  viral 
proteins; red: regulatory proteins; green: auxiliary protein. LTR: Long Terminal Repeat; 
(Blue color): gag: group specific antigen; pro: protease; pol: polymerase; env: envelope; 
(Red color): rex: regulator of expression; tax: transactivator and APH-3: antisense protein 
of HTLV-3; (Green color) RorfII. Note that RorfII shares its first exon with Rex. 
 
5.2. PTLV-3 Auxiliary Proteins 
Since its discovery, it has not been determined whether the HTLV-3 genome, as HTLV-1, encodes 
any auxiliary proteins that would be functionally similar to p12, p13 and p30, which are known to play 
important roles in the viral life cycle in vivo. An antisense transcript was, however, found in 293T cells 
transfected with  an  HTLV-3  molecular clone  [24].  Whether this mRNA encodes  a  protein whose 
functions are similar to those of HBZ remains to be determined. 
Regarding STLV-3, the presence of a doubly spliced mRNA (RorfII) that would encode a 64 amino 
acid highly hydrophobic and leucine rich protein was reported in vivo [24,25] (see Figure 5). The 
function of this protein remains unknown and should be investigated. Whether other accessory proteins 
are encoded from PTLV-3 genomes also remains to be experimentally determined. 
5.3. HTLV-3/STLV-3 Receptor Complex 
In contrast to HTLV-1 and HTLV-2, it was shown that the HTLV-3 surface glycoprotein (gp46 or 
SU) binds to both activated  CD4
+ and  CD8
+ T cells.  HSPGs (heparan sulfate proteoglycans) and  
NRP-1 (neuropilin-1)—two molecules important for HTLV-1 entry—enhance HTLV-3 SU binding 
in vitro  [26].  However,  unlike  HTLV-1,  HTLV-3  SU  can  bind  efficiently  in  the  absence  of  both Viruses 2011, 3                                       
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HSPGs and NRP-1. Studies of entry performed with HTLV-3 env-pseudotyped viruses together with 
SU binding studies revealed that the glucose transporter GLUT-1 functions at a post-binding step. 
Further studies revealed that HTLV-3 SU binds efficiently to naïve CD4
+ T cells, which do not bind 
either HTLV-1 or HTLV-2 SU and do not express detectable levels of HSPGs, NRP-1 and GLUT-1. 
Altogether, these results indicated that the complex of receptor molecules used by HTLV-3 to bind to 
primary T lymphocytes differs from that of both HTLV-1 and HTLV-2 [26].  
6. HTLV-4 Molecular Aspects 
The molecular data on HTLV-4 is very limited. As for PTLV-3, its LTR sequence lacks the distal 
21 bp repeat sequence and therefore contains only two of these elements [21]. A c-Myb binding site is 
also present in the viral promoter. In silico analyses have shown that the Tax protein from HTLV-4 
lacks a PDZ binding motif, as is the case for HTLV-2. The same analyses suggested that the HTLV-4 
provirus might encode 68 and 93 amino acid long auxiliary proteins. The first one, HTLV-4 ORF-IV, 
shares 75% similarity with the HTLV-1 p13
II protein, while the second HTLV-4 ORF-V displays a 
very weak similarity to the C-terminus of the HTLV-2 p28 protein. Finally, an ORF that would allow 
transcription from the 3' LTR is also present in the HTLV-4 genome [21]. Whether these putative 
ORFs encode auxiliary proteins and whether this antisense transcript will functions as the HTLV-1 
HBZ remains to be experimentally determined. For this reason, it seems more appropriate to name this 
protein  APH-4  (Antisense  Protein  of  HTLV-4)  than  HBZ-4.  Unfortunately,  neither  an  HTLV-4 
infected cell line nor an HTLV-4 molecular clone is currently available.  
7. Conclusions  
In conclusion, we would like to reiterate four main points.  
(1) The first point regards the significance of the HTLV indeterminate WB serological patterns in 
Central Africa [27–30] even if, as seen above, in very few cases, these reactivities are linked to the 
presence of a true HTLV-3 and HTLV-4 infection [2,3,31]. In each study that was performed, either in 
an  urban  or  rural  population,  on  blood  donors,  pregnant  women  or  hospitalized  patients,  a  high 
prevalence  of  HTLV  WB  indeterminate  patterns  has  been  reported.  Such  patterns  are  highly 
heterogeneous, ranging from the well-described HGIP  (HTLV gag  indeterminate pattern) to weak 
and/or isolated anti gag
p19 or gag
p24 reactivities [29]. Recently, another frequent indeterminate WB 
pattern was discovered [32]. In most cases, the significance of these WB profiles remains unknown. 
Indeed, in only few cases, an HTLV-1 virus could be isolated and characterized from the PBMCs of 
individuals whose sera displayed an HTLV indeterminate serology [33]. Several other hypotheses have 
been raised including the presence of defective HTLV virus, cross-reactivities with some Plasmodium 
falciparum antigens (as demonstrated in a series of cases from Cameroon) [28], or even cross-reactivity 
with  other  infectious  agent  antigens.  Lastly,  infection  by  another  yet  unknown  HTLV  variant  or 
subtype might also cause such reactivities. 
(2) The second point concerns the prevalence and the distribution of HTLV-3 and 4 viruses in 
Central African populations (Figures 1 and 3), The only data available so far were obtained from a 
series of a few thousand people living mostly in southern Cameroon, an area where STLV-3 infection 
is endemic in several monkey species. Based on these results, one could hypothesize that HTLV-3/4 Viruses 2011, 3                                       
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viruses are also widespread (probably at a low prevalence) in other populations living in areas of 
Cameroon  but  also  in  other  Central/West  African  countries  such  as  Nigeria,  Gabon,  the  Central 
African Republic, the Democratic Republic of Congo, Congo and Equatorial Guinea. Indeed, in such 
areas, HTLV indeterminate serologies are frequent [27–30]. However, to our knowledge, no study 
specifically aimed at detecting those viruses in such countries has been published. We have also to 
keep  in  mind  the  peculiar  epidemiological  situation  of  both  HTLV-1  and  HTLV-2  infection, 
characterized by the presence of high endemic foci, often located nearby a large region with a quite 
low prevalence. This has been recently exemplified in South Cameroon. Indeed, in this large area, 
HTLV-2 infection seems nearly absent, except in the Bakola Pygmy population [34]. Such a situation, 
which is very probably linked to a founder effect followed by favorable viral transmission in a specific 
community, may also be the case for HTLV-3 or -4 infections.  
It  is  also  important  to  note  that  there  is  currently  no  serological  test  available  for  specifically 
screening HTLV-3/4 viruses [31]. In fact, because of the cross-reactivities between some HTLV-1/2 
and HTLV-3/4 antigens, HTLV-1/2 commercial tests are routinely used for the detection of HTLV-3 
and -4. However, the sensitivity of these screening assays for detecting these viruses has not been 
challenged  [17,31].  For  this  reason,  specific  serological  screening  assays  are  needed.  The  use  of 
generic PTLV PCR primers or of HTLV-3/4 specific primers is thus necessary so far for detecting and 
characterizing these viruses in large series of samples with various HTLV indeterminate serologies. 
Obviously, such an approach is costly and time consuming, and does not allow studies on a large 
number of samples. Regarding the presence of HTLV-3 and -4 outside Africa, two recent studies 
showed the absence of HTLV-3 and HTLV-4 infection in patients from the USA, who were suffering 
from large granular leukemia [35,36]. Furthermore, no evidence of HTLV-3 and HTLV-4 infection 
was found in subjects from New York, at risk for retroviral infection [37].   
(3) The third question concerns the modes of transmission of these viruses, their tropism in vivo and 
their  possible  associated  pathology.  Indeed,  a  case-control  study  based  on  a  larger  number  of  
HTLV-3/4 positive individuals would be useful to shed light not only on the possible intra-familial 
transmission of these viruses but also on any possible chronic diseases and/or biological abnormalities 
associated with such viral infection in humans. However, one should keep in mind that, in the HTLV-1 
situation, the incidence of TSP/HAM or ATL diseases is very low and follows a long latency period. If 
HTLV-3 infection is associated with a disease, it might therefore be necessary to follow a large cohort 
of infected individuals for a long period of time before one can observe any disease. Furthermore, the 
selection bias inherent to the enrollment of healthy persons in previous studies greatly limits the ability 
of  identifying  any  acute  or  severe  HTLV-3/4-associated  diseases.  A  sampling  conducted  among 
hospitalized  patients,  including,  among  others,  patients  with  neurological  disorders,  cancer  or 
immunodeficiency  is  thus  necessary,  likely  in  Africa  where  the  virus  is  known  to  be  present. 
Regarding the viral tropism and the pathogenicity of PTLV-3, colonies of infected STLV-3 non-human 
primates are available and should allow some answers to these questions. 
(4) Lastly, we would like to raise the question of the origin of HTLV-3/4 in humans. Even if it 
seems quite understandable that these viruses originally arose through interspecies transmission from 
STLV-3/4 infected monkeys to humans, it is difficult to speculate on the relative part of the direct 
acquisition  stemming  from  infected  monkeys  versus  the  acquisition  from  other  infected  humans 
through sexual activity or breast-feeding. As an example, the immense majority of HTLV-1/2 infected Viruses 2011, 3                                       
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individuals living in Central Africa, have very probably been infected through human contacts (as 
demonstrated by familial studies) and not from NHPs contacts. As seen above, this contrasts with 
foamy viruses, where most, if not all, human carriers were directly infected from foamy virus infected 
NHPs during hunting activities, probably mostly through severe bites [18–20]. Regarding Pyl 43 and 
Lobak18 HTLV-3 strains, some samples were available from spouses, children or other close familial 
relatives (but not parents), and all of them tested HTLV negative by serology and/or PCR studies 
[2,15,38]. For HTLV-4 and the two other HTLV-3 strains, no other familial samples were available to 
investigate the possible human-to-human transmission [3,17]. STLV-3, like STLV-1, is widespread in 
several  non-human  primate  species  living  throughout  the  African  continent.  STLV-3  is  also 
considered, based on current data, to have an ancient origin, greater than that for PTLV-1, but so far 
has  only  limited  prevalence  in  humans.  This  is  rather  consistent  with  primary  simian  transfer. 
However, studies are ongoing to try to discover an HTLV-3 endemic population, as it is known, as 
seen above, for HTLV-2 in some Pygmies from Cameroon [34]. Such studies are necessary to try to 
obtain better insights into the origin and modes of dissemination of HTLV-3 in the African continent. 
Interestingly, even for some HTLV-1 subtypes and for HTLV-2 subtype B, such interrogations on their 
precise origin are still a matter of debate. Indeed, the simian counterpart of the HTLV-1 Cosmopolitan 
subtype A, which is widespread in many high endemic areas of the world (Japan, Caribbean area, 
South  America,  and  others),  is  still  not  yet  know.  The  same  question  remains  for  the  origin  of  
HTLV-2. The simian counterpart (STLV-2) of HTLV-2 is very divergent from the strains present in 
humans, with no evidence of recent interspecies transmission [39].  
In conclusion, and as suggested recently [18,40], the increased hunting activity in a number of 
central  African  countries,  including  Cameroon,  has  increased  the  chances  of  human  exposure  to 
several infectious emerging agents, including retroviruses such as STLV, SIV and foamy viruses. This 
increase  of  hunting  activities  results  from  a  combination  of  urban  demand  for  bush-meat,  greater 
access to NHP’s habitats provided in part by logging roads, better accessibility of fire arms, and finally 
an increase of population living in forest areas and local food needs [18,40]. Future studies will clarify 
whether the recently characterized HTLV-3 and HTLV-4 will emerge, or are emerging, and whether 
they will cause a public health hazard. 
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